Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
$1.00
-0.3%
$0.96
$0.61
$7.38
$15.03M0.041.15 million shs213,987 shs
CervoMed Inc. stock logo
CRVO
CervoMed
$7.41
-2.1%
$7.39
$1.80
$20.63
$64.49M-0.751.35 million shs67,292 shs
MediciNova, Inc. stock logo
MNOV
MediciNova
$1.23
$1.34
$1.12
$2.55
$60.33M0.436,940 shs10,360 shs
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
$0.32
+1.5%
$0.34
$0.30
$0.71
$60.78M0.8411,463 shs7,521 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
0.00%-1.33%+14.35%+6.02%-83.72%
CervoMed Inc. stock logo
CRVO
CervoMed
0.00%+3.64%+6.01%-24.39%-59.82%
MediciNova, Inc. stock logo
MNOV
MediciNova
0.00%-3.15%-3.15%-15.17%-10.87%
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
0.00%-2.96%-6.81%+1.72%-50.91%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
0.677 of 5 stars
0.02.00.00.02.70.01.3
CervoMed Inc. stock logo
CRVO
CervoMed
2.7768 of 5 stars
3.45.00.00.00.61.70.6
MediciNova, Inc. stock logo
MNOV
MediciNova
1.4934 of 5 stars
3.81.00.00.00.00.80.0
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
0.1112 of 5 stars
0.02.00.00.00.01.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
0.00
N/AN/AN/A
CervoMed Inc. stock logo
CRVO
CervoMed
2.89
Moderate Buy$22.57204.61% Upside
MediciNova, Inc. stock logo
MNOV
MediciNova
3.50
Strong Buy$7.00469.11% Upside
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ALLR, MNOV, CRVO, and PYRGF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/16/2025
MediciNova, Inc. stock logo
MNOV
MediciNova
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy ➝ Strong-Buy$6.00 ➝ $5.00
6/11/2025
CervoMed Inc. stock logo
CRVO
CervoMed
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
5/13/2025
CervoMed Inc. stock logo
CRVO
CervoMed
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
5/12/2025
CervoMed Inc. stock logo
CRVO
CervoMed
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$14.00 ➝ $15.00
(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
N/AN/AN/AN/A$1.62 per shareN/A
CervoMed Inc. stock logo
CRVO
CervoMed
N/AN/AN/AN/A$4.50 per shareN/A
MediciNova, Inc. stock logo
MNOV
MediciNova
$1M60.33N/AN/A$1.07 per share1.15
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
$9.14M6.65N/AN/A($0.01) per share-32.45
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
-$24.51MN/A0.00N/AN/AN/A-147.94%-90.33%8/4/2025 (Estimated)
CervoMed Inc. stock logo
CRVO
CervoMed
-$16.29M-$2.18N/AN/AN/A-200.57%-44.07%-40.65%8/8/2025 (Estimated)
MediciNova, Inc. stock logo
MNOV
MediciNova
-$11.04M-$0.23N/AN/AN/AN/A-20.77%-19.68%8/6/2025 (Estimated)
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
-$21.12M-$0.02N/AN/A-115.14%N/A-60.81%N/A

Latest ALLR, MNOV, CRVO, and PYRGF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025N/A
MediciNova, Inc. stock logo
MNOV
MediciNova
-$0.07N/AN/AN/AN/AN/A
8/8/2025Q2 2025
CervoMed Inc. stock logo
CRVO
CervoMed
-$0.55N/AN/AN/A$1.45 millionN/A
5/13/2025Q1 2025
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
-$8.10-$0.25+$7.85-$0.25N/AN/A
5/13/2025Q1 2025
MediciNova, Inc. stock logo
MNOV
MediciNova
-$0.14-$0.06+$0.08-$0.06N/AN/A
5/12/2025Q1 2025
CervoMed Inc. stock logo
CRVO
CervoMed
-$0.60-$0.56+$0.04-$0.56$1.70 million$1.92 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
N/AN/AN/AN/AN/A
CervoMed Inc. stock logo
CRVO
CervoMed
N/AN/AN/AN/AN/A
MediciNova, Inc. stock logo
MNOV
MediciNova
N/AN/AN/AN/AN/A
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
N/A
2.66
2.66
CervoMed Inc. stock logo
CRVO
CervoMed
N/A
9.78
9.78
MediciNova, Inc. stock logo
MNOV
MediciNova
N/A
17.66
17.66
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
N/A
0.60
0.50

Institutional Ownership

CompanyInstitutional Ownership
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
11.53%
CervoMed Inc. stock logo
CRVO
CervoMed
25.15%
MediciNova, Inc. stock logo
MNOV
MediciNova
9.90%
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
0.03%

Insider Ownership

CompanyInsider Ownership
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
0.08%
CervoMed Inc. stock logo
CRVO
CervoMed
35.40%
MediciNova, Inc. stock logo
MNOV
MediciNova
13.60%
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
47.68%
CompanyEmployeesShares OutstandingFree FloatOptionable
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
1015.08 million15.07 millionNot Optionable
CervoMed Inc. stock logo
CRVO
CervoMed
48.70 million5.62 millionNot Optionable
MediciNova, Inc. stock logo
MNOV
MediciNova
1049.05 million42.38 millionOptionable
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
90187.31 million96.34 millionNo Data

Recent News About These Companies

PyroGenesis Announces Extension to Term of Warrants
PyroGenesis Announces First Quarter 2025 Results
PyroGenesis Provides Update on Fumed Silica Project
P. Peter Pascali Updates Early Warning Report

New MarketBeat Followers Over Time

Media Sentiment Over Time

Allarity Therapeutics stock logo

Allarity Therapeutics NASDAQ:ALLR

$1.00 0.00 (-0.34%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$1.00 +0.00 (+0.34%)
As of 07/18/2025 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.

CervoMed stock logo

CervoMed NASDAQ:CRVO

$7.41 -0.16 (-2.11%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$7.42 +0.00 (+0.07%)
As of 07/18/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

MediciNova stock logo

MediciNova NASDAQ:MNOV

$1.23 0.00 (0.00%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$1.24 +0.01 (+0.73%)
As of 07/18/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

PyroGenesis Canada stock logo

PyroGenesis Canada NASDAQ:PYRGF

$0.32 +0.00 (+1.50%)
As of 07/18/2025 03:47 PM Eastern

PyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. The company offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. It provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montreal, Canada.